Johnson & Johnson (J&J) reported a 4.2 percent increase in its worldwide sales to $17.8 billion in the third quarter as compared to the same quarter a year ago, driven by the successful launch of new products and the strength of its core businesses, in particular the pharmaceutical segment.
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.